1Y Target$143.48Near-term target
5Y Target$173.36Compound horizon
10Y Target$254.82Long-dated conviction
FCF$9.2bTTM · 03/26B+FCF $9.2b — strong cash profile, above most peers · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+45.8%TTM YoYARevenue +45.8% — hypergrowth, top decile
D/E0.16A-D/E 0.16 — conservative leverage, strong balance sheet
P/E14.0xB+P/E 14.0 — at or below S&P median, reasonable
PEG2.78CPEG 2.78 — expensive relative to growth rate
Why now
Gold · market cap $114.9b. Down 20% from 52-week high of $134.88 — deep drawdown territory. Revenue growing +46% — in hypergrowth territory. 21 sell-side analysts rate this a Buy with a mean 1-yr target of $143.48 (implying +33% upside).
Moat
Net margin 34% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 26% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 109% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Reserve-replacement treadmill — every barrel or ounce extracted has to be replaced through exploration or acquisition; underspending on replacement reserves shows up in production declines 2-3 years out.
Horizon
1-3 yr $143.48 (21-analyst consensus) — fundamentals + valuation re-rating. 5 yr $173.36 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $254.82 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.